Thiazolidinediones reduce risk of NAFLD - Video

Published On 2021-11-22T14:31:15+05:30 | Updated On 22 Nov 2021 2:31 PM IST

Overview

Thiazolidinediones (TZDs) are beneficial for certain selected patients at risk of Non-Alcoholic Fatty Liver Disease (NAFLD), according to a study published in the Hepatology.

Thiazolidinediones (TZDs) and glucagon-like peptide-1 (GLP-1) receptor agonists are potential pharmacological treatment options for patients at risk of Non-Alcoholic Fatty Liver Disease (NAFLD). Therefore, a group of researchers examined the association between the risk of NAFLD and the use of TZDs and GLP-1 receptor agonists compared with the use of sulfonylureas (SUs) and insulins. Additionally, the researchers calculated the incidence of HCC in users of TZDs and GLP-1 receptor agonists.

For more details, check out the full story on the link below:

Thiazolidinediones May Significantly Reduce Risk Of NAFLD, Finds Study

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751